🚀 VC round data is live in beta, check it out!
Selvita Valuation Multiples
Discover revenue and EBITDA valuation multiples for Selvita and similar public comparables like Mycenax Biotech, Euroapi, Savior Lifetec, Lifecore Biomedical and more.
Selvita Overview
About Selvita
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
Founded
2007
HQ
Employees
969
Website
Financials (LTM)
EV
$264M
Selvita Financials
Selvita reported last 12-month revenue of $102M and EBITDA of $19M.
In the same LTM period, Selvita generated $19M in EBITDA and $1M in net income.
Revenue (LTM)
Selvita P&L
In the most recent fiscal year, Selvita reported revenue of $93M and EBITDA of $15M.
Selvita expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $102M | XXX | $93M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $73M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $19M | XXX | $15M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | (0%) | XXX | XXX | XXX |
| Net Profit | $1M | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | 1% | XXX | (2%) | XXX | XXX | XXX |
| Net Debt | — | — | $26M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Selvita Stock Performance
Selvita has current market cap of $217M, and enterprise value of $264M.
Market Cap Evolution
Selvita's stock price is $11.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $264M | $217M | 0.0% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSelvita Valuation Multiples
Selvita trades at 2.6x EV/Revenue multiple, and 13.8x EV/EBITDA.
EV / Revenue (LTM)
Selvita Financial Valuation Multiples
As of March 24, 2026, Selvita has market cap of $217M and EV of $264M.
Equity research analysts estimate Selvita's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Selvita has a P/E ratio of 197.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $217M | XXX | $217M | XXX | XXX | XXX |
| EV (current) | $264M | XXX | $264M | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 13.8x | XXX | 17.6x | XXX | XXX | XXX |
| EV/EBIT | 61.0x | XXX | (1995.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.6x | XXX | XXX | XXX |
| P/E | 197.2x | XXX | (138.2x) | XXX | XXX | XXX |
| EV/FCF | 44.9x | XXX | 21.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Selvita Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Selvita Margins & Growth Rates
Selvita's revenue in the last 12 month grew by 12%.
Selvita's revenue per employee in the last FY averaged $0.1M.
Selvita's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Selvita's rule of X is 48% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Selvita Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 35% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 48% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 79% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Selvita Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mycenax Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Euroapi | XXX | XXX | XXX | XXX | XXX | XXX |
| Savior Lifetec | XXX | XXX | XXX | XXX | XXX | XXX |
| Lifecore Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Prestige Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Selvita M&A Activity
Selvita acquired XXX companies to date.
Last acquisition by Selvita was on XXXXXXXX, XXXXX. Selvita acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Selvita
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSelvita Investment Activity
Selvita invested in XXX companies to date.
Selvita made its latest investment on XXXXXXXX, XXXXX. Selvita invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Selvita
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Selvita
| When was Selvita founded? | Selvita was founded in 2007. |
| Where is Selvita headquartered? | Selvita is headquartered in Poland. |
| How many employees does Selvita have? | As of today, Selvita has over 969 employees. |
| Is Selvita publicly listed? | Yes, Selvita is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Selvita? | Selvita trades under SLV ticker. |
| When did Selvita go public? | Selvita went public in 2019. |
| Who are competitors of Selvita? | Selvita main competitors are Mycenax Biotech, Euroapi, Savior Lifetec, Lifecore Biomedical. |
| What is the current market cap of Selvita? | Selvita's current market cap is $217M. |
| What is the current revenue of Selvita? | Selvita's last 12 months revenue is $102M. |
| What is the current revenue growth of Selvita? | Selvita revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Selvita? | Current revenue multiple of Selvita is 2.6x. |
| Is Selvita profitable? | Yes, Selvita is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Selvita? | Selvita's last 12 months EBITDA is $19M. |
| What is Selvita's EBITDA margin? | Selvita's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Selvita? | Current EBITDA multiple of Selvita is 13.8x. |
| What is the current FCF of Selvita? | Selvita's last 12 months FCF is $6M. |
| What is Selvita's FCF margin? | Selvita's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Selvita? | Current FCF multiple of Selvita is 44.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.